ClinicalTrials.gg
CompletedNCT03078907TRACEUpdated Mar 30, 2025Results posted

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

A Phase 4 interventional study of Selexipag and Placebo in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 39 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.

Enrollment
5th of 12
108 · median 67
Started
2017
with 1 other
Phase 4
3 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
9 of 12
Actelion

Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 4, and was the 5th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About selexipag

selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing selexipag in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph). The actigraph will collect data on daily life physical activity in the patient's real environment. In addition, the PAH symptoms and their impacts will be assessed by using an electronic patient reported outcome measure in the patient's real environment. Patients will be assigned randomly to either selexipag or placebo.

Read the detailed description

This study is designed as exploratory with the purpose to generate hypotheses on new endpoints

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • daily life
  • physical activity
  • actigraphy
  • PAH-SYMPACT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 75 years old inclusive.
  • Women of must have a negative serum pregnancy test at planned visits and use an acceptable method of from screening up to 30 days after study treatment discontinuation.
  • Symptomatic pulmonary arterial hypertension (PAH) belonging to one of the following subgroups only:

    • Idiopathic
    • Heritable
    • Drug or toxin induced
    • Associated with one of the following: connective tissue disease; infection; corrected simple congenital heart disease.
  • With the following hemodynamic characteristics assessed by right heart catheterization (RHC) prior to randomization:

    • Mean pulmonary artery pressure (mPAP) ≥ 25 mmHg
    • Pulmonary vascular resistance (PVR) ≥ 240 dyn•sec/cm5 (or 3 Wood Units)
    • Pulmonary artery wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤ 15 mmHg.
  • Treatment with an endothelin receptor antagonist (ERA) for at least 90 days and on a stable dose for 30 days prior to randomization.
  • If an ERA is given in combination with a phosphodiesterase-5 (PDE-5) inhibitor or soluble guanylate cyclase (sGC) stimulator, these treatments must be ongoing for at least 90 days and on a stable dose for 30 days prior to randomization.
  • WHO functional class (FC) II or III at randomization
  • 6-minute walk distance (6MWD) ≥ 100 m at screening.
  • Ability to walk without a walking aid.
  • Valid baseline data for daily life physical activity (DLPA) and PAH-SYMPACT®.

Exclusion criteria

Exclusion Criteria:

  • Patients on a PAH-specific monotherapy targeting the nitric oxide pathway (i.e. PDE-5 inhibitor or sGC stimulator).
  • Patients treated with prostacyclin, prostacyclin analog or selexipag within 3 months prior to screening.
  • Any hospitalization during the last 30 days prior to screening.
  • Severe coronary heart disease or unstable angina.
  • Documented severe hepatic impairment or severe renal insufficiency at screening.
  • Participation in a cardio-pulmonary rehabilitation program based on exercise training within 8 weeks prior to screening
  • Any factor or condition likely to affect full participation in the study or compliance with the protocol (such as adherence to protocol mandated procedures), as judged by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Selexipag

    Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.

    Drug: Selexipag

  • Placebo comparator
    Placebo

    Regimen and titration scheme similar to those in the selexipag group

    Drug: Placebo

Interventions

  • Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.

    Also known as: ACT-293987, Uptravi

  • DrugPlacebo

    Matching film coated tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in Minutes

    Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (as defined by Freedson '98 and Koster '16) and daily time spent in moderate-to-vigorous physical activity (MVPA) as defined by Freedson '98 were reported. These variables were assessed by actigraphy and were expressed in minutes. Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

    Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

  2. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Percentage (%)

    Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (Freedson '98), daily time spent in moderate-to-vigorous physical activity (MVPA) (Freedson '98) and dailytime spent in NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in percentage (%). Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

    Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

  3. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts Per Minute (Counts/Minute)

    Change from baseline to Week 24 of the DLPA activity parameter for total daily activities and NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in counts/minutes. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

    Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

  4. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts

    Change from baseline to Week 24 of the DLPA activity parameters for volume of non-sedentary activity (Koster '16)were reported. These variables were assessed by actigraphy and were expressed in counts. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

    Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

  5. Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step Counts

    Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts. Positive change from baseline means improvement.

    Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

  6. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/Minute

    Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts/minute. Positive change from baseline means improvement.

    Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

  7. Change From Baseline to Week 24 in Total Sleep Time (TST)

    TST (in minutes) was assessed by actigraphy.

    Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

  8. Change From Baseline to Week 24 in Wake After Sleep Onset (WASO)

    WASO (in minutes) was assessed by actigraphy.

    Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)

  9. Change From Baseline to Week 24 in Number of Awakenings

    Number of awakenings was assessed by actigraphy.

    Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)

  10. Change From Baseline to Week 24 in Sleep Efficiency (SE)

    SE (in percentage) was assessed by actigraphy. Sleep efficiency was defined as the TST divided by the time in bed (minutes) multiplied by 100. TST was the duration in minutes including REM sleep plus NREM sleep during the time spent in bed.

    Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)

Secondary outcomes

  1. Change From Baseline to Week 24 in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Score

    PAH-SYMPACT has 2 main parts: symptoms (cardiopulmonary and cardiovascular) and impact (physical impacts and cognitive/emotional). The symptom part is a questionnaire completed daily for 7 consecutive days and contains 11 items. The impact part has a 7-day recall period and is completed on 7th day of symptoms questionnaire data collection period. It contains 11 items pertaining to impact of PAH. The average Cardiopulmonary Symptoms and cardiovascular symptoms domain scores are determined based on daily scores of 6 and 5 items, respectively, reported on a 5-point Likert scale with score range from 0=best to 4=worst. The Physical impacts and Cognitive/emotional domain consists of 7 items reported on a 5-point Likert scale (from 0 to 4). The value 0 = "not at all"/"with no difficulty at all" and value 4 = "very much"/"extremely"/ "not able at all". Mean value on each of 7-day period was calculated for each specific domain score and corresponding mean change from baseline was reported.

    Time frame: Baseline and Week 24

  2. Number of Participants With Change From Baseline to Week 24 in World Health Organization Functional Class (WHO FC)

    The WHO FC of pulmonary hypertension is a physical activity rating scale as follows: Class I (No limitation of physical activity); Class II (Slight limitation of physical activity); Class III (Marked limitation of physical activity); and Class IV (Inability to carry out any physical activity without symptoms). The change from baseline in WHO FC was classified into "Improved", "No change" and "Worsened" compared to baseline. Deterioration, No Change, and Improvement are based on shift of risk category (I, II, III, IV) from baseline in WHO Functional Class.

    Time frame: Baseline and Week 24

  3. Change From Baseline to Week 24 in 6-Minute Walk Distance (6MWD)

    The 6MWD was the total distance walked during 6 minutes. Mean change from baseline (distance walked at Week 24 minus distance walked at baseline) was reported.

    Time frame: Baseline and Week 24

  4. Change From Baseline to Week 24 in Borg Dyspnea Score

    The Borg dyspneas score was a self-rating scale to evaluate the severity of dyspnea (from 0 "no shortness of breath at all" to 10 "very, very severe / maximal") shortness of breath. It was completed immediately after the 6-minute walk test at Week 24 and at baseline. Mean change from baseline in scoring was reported.

    Time frame: Baseline and Week 24

  5. Change From Baseline to Week 24 in N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP)

    Change from baseline to Week 24 in NT-pro BNP levels was reported. The negative change from baseline means improvement.

    Time frame: Baseline and Week 24

07

Results

Posted Feb 23, 2021
Limitations and caveats
No hypothesis testing was planned for this exploratory study. Data for sleep outcome measures were not reported because the sleep episodes were not identified due to unexpected inaccuracy in automated sleep detection algorithm which resulted in missing/unreliable sleep data which would mislead the design of future trials and the interpretation of sleep results.

Participant flow

Participant flow — Overall Study
MilestoneSelexipagPlacebo
Started5355
Completed5054
Not completed31
Withdrew: Adverse event20
Withdrew: Other10
Withdrew: Protocol violation01

Outcome measures

PrimaryChange From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in Minutes

Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (as defined by Freedson '98 and Koster '16) and daily time spent in moderate-to-vigorous physical activity (MVPA) as defined by Freedson '98 were reported. These variables were assessed by actigraphy and were expressed in minutes. Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

Time frame:
Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Reported as:
Mean · minutes
Change From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in Minutes
minutesSelexipagPlacebo
Daily time spent in NSA (Freedson '98)-15.2 ± 79.78-25.2 ± 72.47
Daily time spent in MVPA (Freedson '98)0.2 ± 34.48-1.9 ± 34.26
Daily time spent in NSA (Koster'16)-0.7 ± 72.50-15.0 ± 62.27
Statistical analysis
  • Selexipag vs Placebo · ANCOVA · Least square (ls) mean: 13.79 · 95% CI 13.366 to 40.944
  • Selexipag vs Placebo · ANCOVA · Ls means: 2.31 · 95% CI -10.782 to 15.396
  • Selexipag vs Placebo · ANCOVA · Ls mean: 17.81 · 95% CI -6.003 to 41.619
PrimaryChange From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Percentage (%)

Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (Freedson '98), daily time spent in moderate-to-vigorous physical activity (MVPA) (Freedson '98) and dailytime spent in NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in percentage (%). Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

Time frame:
Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Reported as:
Mean · Percentage of daily time spent
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Percentage (%)
Percentage of daily time spentSelexipagPlacebo
Daily time spent in NSA (%), Freedson '980.08 ± 7.265-0.10 ± 6.439
Daily time spent in MVPA (%), Freedson '980.23 ± 3.3420.32 ± 3.513
Daily time spent in NSA (%), Koster '160.80 ± 7.1580.00 ± 6.269
Statistical analysis
  • Selexipag vs Placebo · ANCOVA · Ls mean: 0.67 · 95% CI -1.713 to 3.060
  • Selexipag vs Placebo · ANCOVA · Ls mean: -0.05 · 95% CI -1.351 to 1.258
  • Selexipag vs Placebo · ANCOVA · Ls mean: 1.26 · 95% CI -1.104 to 3.618
PrimaryChange From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts Per Minute (Counts/Minute)

Change from baseline to Week 24 of the DLPA activity parameter for total daily activities and NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in counts/minutes. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

Time frame:
Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Reported as:
Mean · counts/minute
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts Per Minute (Counts/Minute)
counts/minuteSelexipagPlacebo
Total daily activities29.3 ± 337.1818.8 ± 342.77
NSA, Koster '1636.1 ± 342.1116.8 ± 351.08
Statistical analysis
  • Selexipag vs Placebo · ANCOVA · Ls mean: 20.66 · 95% CI -105.632 to 146.958
  • Selexipag vs Placebo · ANCOVA · Ls means: 27.52 · 95% CI -101.945 to 156.976
PrimaryChange From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts

Change from baseline to Week 24 of the DLPA activity parameters for volume of non-sedentary activity (Koster '16)were reported. These variables were assessed by actigraphy and were expressed in counts. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.

Time frame:
Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Reported as:
Mean · counts
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts
countsSelexipagPlacebo
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts3898 ± 345872-49187 ± 343402.2
Statistical analysis
  • Selexipag vs Placebo · ANCOVA · Ls means: 58409 · 95% CI -70444 to 187263
PrimaryChange From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step Counts

Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts. Positive change from baseline means improvement.

Time frame:
Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Reported as:
Mean · step counts
Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step Counts
step countsSelexipagPlacebo
Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step Counts-32.4 ± 1288.64-170.9 ± 1076.87
Statistical analysis
  • Selexipag vs Placebo · ANCOVA · Ls means: 201.59 · 95% CI -242.977 to 646.163
PrimaryChange From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/Minute

Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts/minute. Positive change from baseline means improvement.

Time frame:
Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Reported as:
Mean · step counts/minute
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/Minute
step counts/minuteSelexipagPlacebo
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/Minute0.0 ± 1.250.0 ± 1.04
Statistical analysis
  • Selexipag vs Placebo · ANCOVA · Ls means: 0.07 · 95% CI -0.366 to 0.510
PrimaryChange From Baseline to Week 24 in Total Sleep Time (TST)

TST (in minutes) was assessed by actigraphy.

Time frame:
Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)

No measurements were reported for this outcome.

PrimaryChange From Baseline to Week 24 in Wake After Sleep Onset (WASO)

WASO (in minutes) was assessed by actigraphy.

Time frame:
Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)

No measurements were reported for this outcome.

PrimaryChange From Baseline to Week 24 in Number of Awakenings

Number of awakenings was assessed by actigraphy.

Time frame:
Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)

No measurements were reported for this outcome.

PrimaryChange From Baseline to Week 24 in Sleep Efficiency (SE)

SE (in percentage) was assessed by actigraphy. Sleep efficiency was defined as the TST divided by the time in bed (minutes) multiplied by 100. TST was the duration in minutes including REM sleep plus NREM sleep during the time spent in bed.

Time frame:
Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 24 in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Score

PAH-SYMPACT has 2 main parts: symptoms (cardiopulmonary and cardiovascular) and impact (physical impacts and cognitive/emotional). The symptom part is a questionnaire completed daily for 7 consecutive days and contains 11 items. The impact part has a 7-day recall period and is completed on 7th day of symptoms questionnaire data collection period. It contains 11 items pertaining to impact of PAH. The average Cardiopulmonary Symptoms and cardiovascular symptoms domain scores are determined based on daily scores of 6 and 5 items, respectively, reported on a 5-point Likert scale with score range from 0=best to 4=worst. The Physical impacts and Cognitive/emotional domain consists of 7 items reported on a 5-point Likert scale (from 0 to 4). The value 0 = "not at all"/"with no difficulty at all" and value 4 = "very much"/"extremely"/ "not able at all". Mean value on each of 7-day period was calculated for each specific domain score and corresponding mean change from baseline was reported.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Score
units on a scaleSelexipagPlacebo
Cardiopulmonary symptoms-0.030 ± 0.4160-0.080 ± 0.2564
Cardiovascular symptoms0.010 ± 0.3522-0.045 ± 0.3029
Physical impact-0.043 ± 0.5932-0.074 ± 0.5470
Cognitive/emotional impact0.000 ± 0.5311-0.090 ± 0.5992
SecondaryNumber of Participants With Change From Baseline to Week 24 in World Health Organization Functional Class (WHO FC)

The WHO FC of pulmonary hypertension is a physical activity rating scale as follows: Class I (No limitation of physical activity); Class II (Slight limitation of physical activity); Class III (Marked limitation of physical activity); and Class IV (Inability to carry out any physical activity without symptoms). The change from baseline in WHO FC was classified into "Improved", "No change" and "Worsened" compared to baseline. Deterioration, No Change, and Improvement are based on shift of risk category (I, II, III, IV) from baseline in WHO Functional Class.

Time frame:
Baseline and Week 24
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline to Week 24 in World Health Organization Functional Class (WHO FC)
ParticipantsSelexipagPlacebo
Deterioration21
No change3343
Improvement910
SecondaryChange From Baseline to Week 24 in 6-Minute Walk Distance (6MWD)

The 6MWD was the total distance walked during 6 minutes. Mean change from baseline (distance walked at Week 24 minus distance walked at baseline) was reported.

Time frame:
Baseline and Week 24
Reported as:
Mean · meters
Change From Baseline to Week 24 in 6-Minute Walk Distance (6MWD)
metersSelexipagPlacebo
Change From Baseline to Week 24 in 6-Minute Walk Distance (6MWD)18.3 ± 54.479.8 ± 60.72
SecondaryChange From Baseline to Week 24 in Borg Dyspnea Score

The Borg dyspneas score was a self-rating scale to evaluate the severity of dyspnea (from 0 "no shortness of breath at all" to 10 "very, very severe / maximal") shortness of breath. It was completed immediately after the 6-minute walk test at Week 24 and at baseline. Mean change from baseline in scoring was reported.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in Borg Dyspnea Score
units on a scaleSelexipagPlacebo
Change From Baseline to Week 24 in Borg Dyspnea Score-0.25 ± 2.1220.37 ± 1.869
SecondaryChange From Baseline to Week 24 in N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP)

Change from baseline to Week 24 in NT-pro BNP levels was reported. The negative change from baseline means improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · nanogram per liter (ng/L)
Change From Baseline to Week 24 in N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP)
nanogram per liter (ng/L)SelexipagPlacebo
Change From Baseline to Week 24 in N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP)-153.8 ± 609.3281.8 ± 316.54

Adverse events

Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag0/53 (0%)3/53 (5.7%)52/53 (98.1%)
Placebo0/55 (0%)6/55 (10.9%)52/55 (94.5%)
Most frequent serious events
Most frequent serious events
EventSelexipagPlacebo
Atrial FlutterCardiac disorders1/531/55
Right Ventricular FailureCardiac disorders1/530/55
MigraineNervous system disorders1/530/55
Vision BlurredEye disorders0/531/55
GlossitisGastrointestinal disorders0/531/55
PneumoniaInfections and infestations0/531/55
Multiple Sclerosis RelapseNervous system disorders0/531/55
SyncopeNervous system disorders0/531/55
Pleural EffusionRespiratory, thoracic and mediastinal disorders0/531/55
Thyroid Nodule RemovalSurgical and medical procedures0/531/55
Most frequent other events
Showing 10 of 32
Most frequent other events
EventSelexipagPlacebo
HeadacheNervous system disorders41/5326/55
DiarrhoeaGastrointestinal disorders28/5323/55
NauseaGastrointestinal disorders22/5315/55
Pain in JawMusculoskeletal and connective tissue disorders20/535/55
NasopharyngitisInfections and infestations5/5314/55
VomitingGastrointestinal disorders13/534/55
ArthralgiaMusculoskeletal and connective tissue disorders11/538/55
Pain in ExtremityMusculoskeletal and connective tissue disorders11/531/55
DizzinessNervous system disorders7/537/55
Non-Cardiac Chest PainGeneral disorders2/537/55

Baseline characteristics

Age, Continuous
Age, Continuous(years)SelexipagPlaceboTotal
Mean49 ± 14.7549.8 ± 13.6349.4 ± 14.13
Sex: Female, Male
Sex: Female, Male(Participants)SelexipagPlaceboTotal
Female354277
Male181331
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SelexipagPlaceboTotal
American Indian or Alaska Native000
Asian437
Native Hawaiian or Other Pacific Islander000
Black or African American202
White445296
More than one race000
Unknown or Not Reported303
Region of Enrollment
Region of Enrollment(participants)SelexipagPlaceboTotal
AUSTRIA011
FRANCE202
GERMANY6511
IRELAND112
NORWAY011
PORTUGAL336
SWEDEN404
SWITZERLAND011
UNITED KINGDOM313566
UNITED STATES6814
08

Study locations

39 sites
  • LA Biomedical Research Institute
    Torrance, California 90502, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Kentuckiana Pulmonary Research Center
    Louisville, Kentucky 40202, United States
  • Tufts Medical Center, Pulmonary/Critical Care & Sleep
    Boston, Massachusetts 02111, United States
  • University of Nebraska Medical Center, Pulmonary, Critical Care & Sleep Medicine Division
    Omaha, Nebraska 68198, United States
  • NYU Winthrop Hospital
    Mineola, New York 11501, United States
  • UNC Pulmonary Speciality Clinic
    Chapel Hill, North Carolina 27599, United States
  • Duke University School of Medicine, Duke Pulmonary Vascular Disease center
    Durham, North Carolina 27710, United States
  • University of Cincinnati, Heart, Lung and Vascular Institute
    Cincinnati, Ohio 45267-0564, United States
  • CCF- Akron General Medical Hospital
    Cleveland, Ohio 44307, United States
  • Integris Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
  • University of Pennsylvania, Pulmonary Vascular Disease Program
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center, Care Medicine
    Nashville, Tennessee 37232-2650, United States
  • Methodist Clinical Trials
    San Antonio, Texas 78229, United States
  • University of Texas Health Science Center (San Antonio)
    San Antonio, Texas 78229, United States
  • Medizinische Universität Innsbruck (MUI), Abt. für Pneumologie, Haus 2
    Innsbruck, 06020, Austria
  • Krankenhaus der Elisabethinen, Servicestelle Klinische Studien
    Linz, 4020, Austria
  • Hôpital Bicêtre, ervice de Pneumologie et Réanimation respiratoire
    Le Kremlin-Bicêtre, 94270, France
  • CHRU de Lille - Hôpital Albert Calmette, Service de cardiologie
    Lille, 59000, France
  • Hospital Larrey CHU de Toulouse
    Toulouse, 31059, France
  • Universitätsklinikum Giessen
    Giessen, 35392, Germany
  • Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin
    Köln, 50937, Germany
  • Universitätsklinikum Leipzig AöR, Abteilung Pneumologie
    Leipzig, 04103, Germany
  • Katholisches Klinikum Lünen/Werne GmbH, Haus E
    Lünen, 44534, Germany
  • Mater Misericordiae University Hospital
    Dublin, D07 R2WY, Ireland
  • Oslo University Hospital, dept of cardiology
    Oslo, 0372, Norway
  • Centro Hospitalar e Universitário de Coimbra, Serviço de Cardiologia
    Coimbra, 3000-075, Portugal
  • Hospital Geral de Santo António-DEFI
    Porto, 4099-001, Portugal
  • Sahlgrenska University Hospital, Gothenburg
    Gothenburg, 413 45, Sweden
  • Skåne University Hospital, VO Hjärt och Lungmedicin
    Lund, 221 85, Sweden
  • Kantonsspital St. Gallen, Klinik für Pneumologie und Schlafmedizin
    St. Gallen, 9007, Switzerland
  • Universitaetsspital Zurich, Klinik für Pneumologie C HOER 11
    Zurich, 8091, Switzerland
  • Papworth Hospital, Pulmonary Vascular Disease Unit
    Cambridge, Cb23 3RE, United Kingdom
  • Golden Jubilee National Hospital, Scottish Pulmonary Vascular Unit
    Clydebank, G81 4DY, United Kingdom
  • The Royal Free Hospital, Cardiology Department
    London, NW3 2QG, United Kingdom
  • Royal Brompton Hospital, Hypertension
    London, SW3 6NP, United Kingdom
  • Hammersmith Hospital
    London, W12 0HS, United Kingdom
  • Freeman Hospital, Cardiothoracic Department
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Royal Hallamshire Hospital, Pulmonary Vascular Medicine
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Howard LS, Rosenkranz S, Frantz RP, Hemnes AR, Pfister T, Hsu Schmitz SF, Skara H, Humbert M, Preston IR. Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE). Chest. 2023 Feb;163(2):407-418. doi: 10.1016/j.chest.2022.08.2231. Epub 2022 Sep 8. PubMed 36089068 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Feb 2020, 27 months.

Results were first posted in Feb 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2017
First posted
Mar 14, 2017
StartActual
Nov 8, 2017
Primary completionActual
Feb 10, 2020
CompletionActual
Feb 10, 2020
Results first posted
Feb 23, 2021
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03078907
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Mar 14, 2017
Start date
Nov 8, 2017
Primary completion
Feb 10, 2020
Completion
Feb 10, 2020
Results posted
Feb 23, 2021
Last update
Mar 30, 2025

Study contacts

Thomas Pfister
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion